Alseres Pharmaceuticals (Alseres Pharmaceuticals) EV-to-EBITDA : -0.06 (As of May. 22, 2024)

Alseres Pharmaceuticals EV-to-EBITDA Chart

Alseres Pharmaceuticals Annual Data
	Trend	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13
EV-to-EBITDA		Get a 7-Day Free Trial					-6.55	-12.89	-25.96	-7.86	-17.85

Alseres Pharmaceuticals Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
EV-to-EBITDA	Get a 7-Day Free Trial															-7.44	-8.61	-17.85	-12.65	-12.86

Competitive Comparison of Alseres Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, Alseres Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alseres Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alseres Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Alseres Pharmaceuticals's EV-to-EBITDA falls into.

Alseres Pharmaceuticals EV-to-EBITDA Calculation

Alseres Pharmaceuticals's EV-to-EBITDA for today is calculated as:

Alseres Pharmaceuticals's current Enterprise Value is $0.03 Mil.
Alseres Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alseres Pharmaceuticals  (OTCPK:ALSE) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Alseres Pharmaceuticals's PE Ratio for today is calculated as:

Alseres Pharmaceuticals's share price for today is $0.01.
Alseres Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $-100.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Alseres Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Alseres Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Business Description